Bing

SEARCH HISTORY

Dendreon (DNDN) stock opened slightly higher this morning, despite the fact that Dendreon earnings for Q3 rolled in even worse than expected. Product revenue for DNDN — which is to say revenue from its only product, prostate-cancer drug Provenge — fell ...
Investor Place · ByJames Brumley · 11/12/2013
Dendreon Corporation (DNDN) stock is down about 64% during premarket trade today, after the company announced it had reached an agreement with bondholders for a financial restructure and filed for Chapter 11 bankruptcy protection with the Bankruptcy …
bidnessetc.com · 11/11/2014
Dendreon Corporation (NASDAQ:DNDN) was in 13 hedge funds’ portfolio at the end of March. DNDN has seen a decrease in support from the world’s most elite money managers recently. There were 13 hedge funds in our database with DNDN positions …
INSIDER MONKEY · 6/6/2013
More from Bing News
Many investors appear to be quite bearish on Dendreon Corporation (DNDN), especially if you look at the percentage of the float that is sold short for this stock. Currently, 26.92% of the float is sold short, suggesting an extreme level of bearishness for ...
Yahoo Finance · 6/26/2014
Many investors appear to be quite bearish on Dendreon Corporation ( DNDN), especially if you look at the percentage of the float that is sold short for this stock. Currently, 26.96% of the float is sold short, suggesting an extreme level of bearishness for ...
NASDAQ · 6/2/2014
Followers of Dendreon (NASDAQ:DNDN) may have noticed that since May, the stock has halted its downward march toward zero, finding support at $2. These are the same shares that traded as high as $56 after FDA approval in 2010, and boasted a market ...
Seeking Alpha · 7/8/2014
Trade-Ideas LLC identified Dendreon ( DNDN) as a pre-market mover with heavy volume candidate. In addition to specific proprietary factors, Trade-Ideas identified Dendreon as such a stock due to the following factors: DNDN has an average dollar-volume (as ...
The Street · 3/3/2014
As for potential cancer stock peers, large cap Celgene Corporation is focused on the discovery, the development and the commercialization of products for the treatment of cancer and other severe, immune, inflammatory conditions; small cap Dendreon ...
Smallcap Network · ByJohn Udovich · 1/8/2014
My valuation model shows $1.5 billion in Provenge revenue should equate to about $30 on DNDN stock today. [Shares traded above $43 Monday—Editor.] Considering the potential for immediate off-label use in earlier stages of prostate cancer, I think there ...
The Money Show · 5/2/2011
There was an interesting twist in the ongoing Dendreon Corp. (NASDAQ: DNDN) story that developed after 5:00 PM Friday. There was a whole series of FORM 4 filings insider sales filings with the SEC. While it is obvious that most of these were options ...
24/7 Wall ST · 5/2/2009